Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.72 |
| ▸ | IGF1R | P08069 | 3/20 | 0.72 |
| ▸ | JAK2 | O60674 | 10/20 | 0.58 |
| ▸ | JAK3 | P52333 | 5/20 | 0.57 |
| ▸ | JAK1 | P23458 | 3/20 | 0.57 |
| ▸ | TYK2 | P29597 | 3/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | OPA1 | O60313 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27658496 | 0.93 | CDK2 (0.73) | CDK2IGF1RJAK2JAK3PLK4 | |
| SCHEMBL3537388 | 0.88 | CDK2 (0.67) | CDK2IGF1RJAK2PLK4MAPK8 | |
| SCHEMBL4805850 | 0.87 | CDK2 (0.68) | CDK2IGF1RHDAC1MAPK8MAPK9 | |
| SCHEMBL4811064 | 0.84 | CDK2 (0.64) | CDK2IGF1RHDAC1MAPK8MAPK9 | |
| SCHEMBL28718949 | 0.83 | CDK2 (0.61) | CDK2IGF1RJAK2PLK4MAPK8 | |
| SCHEMBL29543751 | 0.83 | CDK2 (0.61) | CDK2IGF1RJAK2PLK4MAPK8 | |
| SCHEMBL7978513 | 0.82 | CDK2 (0.69) | CDK2IGF1RHDAC1MAPK8MAPK9 | |
| SCHEMBL4813320 | 0.82 | CDK2 (0.61) | CDK2IGF1RHDAC1MAPK8MAPK9 | |
| SCHEMBL1684872 | 0.81 | CDK2 (0.70) | CDK2IGF1RHDAC1MAPK8MAPK9 | |
| SCHEMBL4811306 | 0.80 | CDK2 (0.72) | CDK2IGF1RHDAC1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | claimed |
| CN-1294131-C | Pyrimidine compound | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | claimed |
| CN-1537112-A | Pyrimidine compound | — | 2004-10-13 | — | — | CN | claimed |
| US-20040077642-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | claimed |
| EP-1373266-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | claimed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | claimed |
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| CN-1294131-C | Pyrimidine compound | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| CN-1537112-A | Pyrimidine compound | — | 2004-10-13 | — | — | CN | disclosed |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKI CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040077642-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| EP-1373266-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077642-A1 | Pyrimidine compounds | TYMP, DPYD, TYMS | CDK2 49/4885IGF1R 4669/4885JAK2 842/4885 |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | CYP1B1, MAOB, HTR1B | CDK2 1016/4885IGF1R 1336/4885JAK2 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.